Market Place
Sourcing Support
Agenus To Host Mar 2026 Webcast On BOT + BAL Strategy
26 Mar 2026 //
BUSINESSWIRE
Agenus Shows Survival Stratification in MSS mCRC
19 Feb 2026 //
BUSINESSWIRE
Agenus To Unveil Systemic, Tumor Inflammation Biomarker Data
09 Feb 2026 //
BUSINESSWIRE
Agenus Expands Medical Affairs For Botensilimab & Blstilimab
21 Jan 2026 //
BUSINESSWIRE
Agenus To Host First 2026 Stakeholder Webcast
20 Jan 2026 //
BUSINESSWIRE
Zydus Lifesciences Completes the Acquisition of Agenus Facility
15 Jan 2026 //
PR NEWSWIRE
France Expands Agenus` Botensilimab + Balstilimab Access
12 Jan 2026 //
BUSINESSWIRE
Agenus Reveals Strong Ovarian Cancer Responses With Botensilimab
23 Dec 2025 //
BUSINESSWIRE
Agenus Hosts End-Of-Year Webcast On GI Oncology Progress
19 Nov 2025 //
BUSINESSWIRE
Agenus Reveals 39% Two-Year Survival Rate With BOT/BAL Tumors
17 Oct 2025 //
BUSINESSWIRE
Agenus Showcases BOT/BAL Global Momentum In October Stakeholder
16 Oct 2025 //
BUSINESSWIRE
France Approves Agenus’ BOT/BAL for Reimbursed Access in Cancer
09 Sep 2025 //
BUSINESSWIRE
Agenus to Present Botensilimab/Balstilimab Data at ESMO 2025
25 Jul 2025 //
BUSINESSWIRE
Agenus’ BOT/BAL Reaches 42% 2-Year Survival in MSS CRC
07 Jul 2025 //
BUSINESSWIRE
Zydus Partners with Agenus for Cancer Therapies in India
04 Jun 2025 //
BUSINESSWIRE
Zydus to acquire Agenus` U.S. facilities for biologics CDMO
03 Jun 2025 //
PR NEWSWIRE
Agenus`s Botensilimab Immune Activation In MSS Colorectal Cancer
30 May 2025 //
BUSINESSWIRE
Agenus presents BOT/BAL Neoadjuvant Pan-Cancer Data at AACR
28 Apr 2025 //
BUSINESSWIRE
Agenus presents BOT/BAL Data in Liver Cancer at AACR 2025
25 Apr 2025 //
BUSINESSWIRE
Agenus to Present Botensilimab & Balstilimab at ASCO 2025
23 Apr 2025 //
BUSINESSWIRE
Agenus Highlights Impact Of Key Immuno-Oncology Data
26 Feb 2025 //
BUSINESSWIRE
Agenus Presents Botensilimab/Balstilimab Data In Gastric Cancer
24 Feb 2025 //
BUSINESSWIRE
Agenus Publishes Botensilimab, Balstilimab Data In JCO
29 Jan 2025 //
BUSINESSWIRE
Agenus Announces 5 Presentations at ASCO GI on Colorectal Cancers
18 Dec 2024 //
BUSINESSWIRE
Tanner Expands Access To Botensilimab, Balstilimab With Agenus
12 Dec 2024 //
BUSINESSWIRE
Botensilimab/Balstilimab Data In Refractory Sarcomas Presented At ESMO
13 Sep 2024 //
BUSINESSWIRE
Botensilimab/Balstilimab Sarcoma Data To Be Presented At ESMO
09 Sep 2024 //
BUSINESSWIRE
Xencor Announces Autoimmune And Oncology Drug Candidates
09 Sep 2024 //
BUSINESSWIRE
Botensilimab Mss Crc Breakthrough: Balstilimab Data Presented Asco 2024
23 May 2024 //
BUSINESSWIRE
Botensilimab/Balstilimab MSS CRC Data at ASCO 2024
24 Apr 2024 //
BUSINESSWIRE
Agenus Announces Preclinical Data on BMS-986442 (AGEN1777) at AACR 2024
06 Mar 2024 //
BUSINESSWIRE
Agenus Unveils New and Updated Botensilimab Data in Colorectal
22 Oct 2023 //
BUSINESSWIRE
Agenus Completes Enrollment in Randomized Phase 2 Clinical Trial of Botensilimab
10 Oct 2023 //
BUSINESSWIRE
Agenus Botensilimab/Balstilimab Data in Sarcomas Selected for Presentation
28 Jul 2023 //
BUSINESSWIRE
Agenus Presents Positive Efficacy and Safety Outcomes for AGEN2373 at ASCO
05 Jun 2023 //
BUSINESSWIRE
Agenus Receives Fast Track Designation for Botensilimab and Balstilimab
17 Apr 2023 //
BUSINESSWIRE
Agenus Presents Data Demonstrating Durable Responses of Botensilimab/Balstilimab
23 Jan 2023 //
GLOBENEWSWIRE
